AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30185192 — intervention group
Group type: EXPERIMENTAL
Intervention: REP + coaching + facilitation
Number of subjects: 200
Study 30185192 — intervention group
Group type: COMPARATOR
Intervention: REP
Number of subjects: 200
Study 27258183 — intervention group
Group type: EXPERIMENTAL
Intervention: Parkinson disease patients walking in medication-off condition
Number of subjects: 23
Study 27258183 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects walking at preferred and slow speeds
Number of subjects: 23
Study 24762424 — intervention group
Group type: COMPARATOR
Intervention: Warm environment (25.0 ± 0.1 °C, 50.8 ± 1.5% RH)
Number of subjects: 10
Study 24762424 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold environment (0.4 ± 1.0 °C, 68.8 ± 7.5% RH)
Number of subjects: 10
Study 22410606 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercise program (8 weeks of individual exercise education and exercise adherence strategy)
Number of subjects: 24
Study 22410606 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise program)
Number of subjects: 24
Study 20236661 — intervention group
Group type: EXPERIMENTAL
Intervention: Natalizumab plus interferon beta‐1a
Number of subjects: 1171
Study 20236661 — intervention group
Group type: COMPARATOR
Intervention: Interferon beta‐1a alone
Number of subjects: 1171
Study 19065889 — intervention group
Group type: EXPERIMENTAL
Intervention: Compound Tongfu Granule (CTG)
Number of subjects: 50
Study 19065889 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study 15839187 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone plus glipizide
Number of subjects: 225
Study 15839187 — intervention group
Group type: COMPARATOR
Intervention: Glipizide monotherapy
Number of subjects: 225
Study 12456522 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus the completion of an advance directive
Number of subjects: 156
Study 12456522 — intervention group
Group type: COMPARATOR
Intervention: Usual psychiatric care (control)
Number of subjects: 156
Study 11077940 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid lysozyme level in tuberculous pleural effusions
Number of subjects: 42
Study 11077940 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid lysozyme level in tuberculous ascites
Number of subjects: 42
Study 11077940 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid lysozyme level in tuberculous pericardial effusions
Number of subjects: 42
Study 11077940 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid lysozyme level in confirmed tuberculous pleural effusion patients
Number of subjects: 42
Study 11077940 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid lysozyme level cut-off
Number of subjects: 42
Study 11077940 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid/serum lysozyme ratio cut-off
Number of subjects: 42
Study 11077940 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between fluid and serum lysozyme levels in tuberculous effusions
Number of subjects: 42
Study 8869440 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil sodium (NS), 2 puffs (2 mg puff-1) administered three times a day via a spacer device and face mask
Number of subjects: 15
Study 8869440 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil sodium (NS)
Number of subjects: 15
Study 8869440 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 6702646 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (N), 20 mg, 3 times daily
Number of subjects: 14
Study 6702646 — intervention group
Group type: COMPARATOR
Intervention: Placebo (C)
Number of subjects: 14
Study 31205087 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratracheal instillation of R‐spondin1
Number of subjects: 0
Study 31205087 — intervention group
Group type: EXPERIMENTAL
Intervention: Knockdown of pulmonary R‐spondin1
Number of subjects: 0
Study 31205087 — intervention group
Group type: EXPERIMENTAL
Intervention: R‐spondin1 treatment
Number of subjects: 0
Study 31205087 — intervention group
Group type: COMPARATOR
Intervention: Mechanical ventilation
Number of subjects: 0
Study 29664813 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomograms predicting overall survival (OS)
Number of subjects: 450
Study 29664813 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomograms predicting cancer-specific survival (CSS)
Number of subjects: 450
Study 29664813 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomograms predicting OS and CSS
Number of subjects: 450
Study 27401357 — intervention group
Group type: EXPERIMENTAL
Intervention: Optometrists
Number of subjects: 96
Study 27401357 — intervention group
Group type: COMPARATOR
Intervention: Ophthalmologists
Number of subjects: 96
Study 25136077 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional programming (ventricular tachycardia zone ≥170 beats per minute)
Number of subjects: 1500
Study 25136077 — intervention group
Group type: COMPARATOR
Intervention: High-rate programming (ventricular tachycardia zone ≥200 beats per minute)
Number of subjects: 1500
Study 25136077 — intervention group
Group type: COMPARATOR
Intervention: Delayed programming (60-second delay before therapy ≥170 beats per minute)
Number of subjects: 1500
Study 25136077 — intervention group
Group type: EXPERIMENTAL
Intervention: Appropriate shocks
Number of subjects: 1500
Study 25136077 — intervention group
Group type: EXPERIMENTAL
Intervention: Inappropriate therapy
Number of subjects: 1500
Study 25136077 — intervention group
Group type: EXPERIMENTAL
Intervention: Appropriate antitachycardia pacing only
Number of subjects: 1500
Study 23188600 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 80
Study 23188600 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 19481335 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily tamoxifen 20mg continuously (daily group)
Number of subjects: 80
Study 19481335 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly tamoxifen 20mg after the first 8 weeks of daily treatment (weekly group)
Number of subjects: 80
Study 19481335 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily tamoxifen 20mg continuously (daily group) and Weekly tamoxifen 20mg after the first 8 weeks of daily treatment (weekly group)
Number of subjects: 80
Study 17353504 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide LAR 0.8 mg
Number of subjects: 45
Study 17353504 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide LAR 2.0 mg
Number of subjects: 45
Study 17353504 — intervention group
Group type: COMPARATOR
Intervention: Placebo LAR
Number of subjects: 45
Study 15911118 — intervention group
Group type: EXPERIMENTAL
Intervention: Coupled bilateral protocol (wrist/finger movements on unimpaired limb with active stimulation on impaired limb)
Number of subjects: 26
Study 15911118 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral/active stimulation (neuromuscular electromyogram-triggered stimulation on impaired wrist/fingers)
Number of subjects: 26
Study 15911118 — intervention group
Group type: COMPARATOR
Intervention: No protocol (control group)
Number of subjects: 26
Study 11746068 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity exercise regimen
Number of subjects: 0
Study 11746068 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (not specified)
Number of subjects: 0
Study 9436565 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine (3 microg x kg(‐1) x min(‐1))
Number of subjects: 30
Study 9436565 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoximone (200 microg/kg)
Number of subjects: 30
Study 9436565 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine (0.05 microg x kg(‐1) x min(‐1))
Number of subjects: 30
Study 11767429 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin puncture (1 mm deep)
Number of subjects: 50
Study 11767429 — intervention group
Group type: COMPARATOR
Intervention: No skin puncture
Number of subjects: 50
Study 3619195 — intervention group
Group type: EXPERIMENTAL
Intervention: terfenadine 180 mg
Number of subjects: 9
Study 3619195 — intervention group
Group type: EXPERIMENTAL
Intervention: astemizole
Number of subjects: 9
Study 3619195 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 9
Study 2746641 — intervention group
Group type: EXPERIMENTAL
Intervention: Single 50‐mg dose of riboflavin
Number of subjects: 0
Study 2746641 — intervention group
Group type: EXPERIMENTAL
Intervention: More frequent dosage of riboflavin
Number of subjects: 0
Study 2746641 — intervention group
Group type: EXPERIMENTAL
Intervention: Riboflavin as a tracer
Number of subjects: 0
Study 4349414 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium amylobarbitone
Number of subjects: 8
Study 4349414 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzoctamine
Number of subjects: 8
Study 4349414 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 4349414 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawal from drugs
Number of subjects: 8
Study 31350629 — intervention group
Group type: EXPERIMENTAL
Intervention: Icon® resin infiltration
Number of subjects: 0
Study 31350629 — intervention group
Group type: COMPARATOR
Intervention: Clinpro™ XT varnish
Number of subjects: 0
Study 27651330 — intervention group
Group type: EXPERIMENTAL
Intervention: Extremely Randomized Trees (ERT) classifier
Number of subjects: 49
Study 27651330 — intervention group
Group type: COMPARATOR
Intervention: Support Vector Machine (SVM)
Number of subjects: 49
Study 25947394 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration of Lipo‐PGE1 (Group A)
Number of subjects: 68
Study 25947394 — intervention group
Group type: COMPARATOR
Intervention: No Lipo‐PGE1 administration (Group B)
Number of subjects: 68
Study 23092171 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% CHX application
Number of subjects: 90
Study 23092171 — intervention group
Group type: COMPARATOR
Intervention: No CHX application
Number of subjects: 90
Study 21602833 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin GITS 4 mg once daily plus sildenafil 25‐100 mg on demand (Group A)
Number of subjects: 250
Study 21602833 — intervention group
Group type: COMPARATOR
Intervention: Sildenafil 25‐100 mg on demand (Group B)
Number of subjects: 250
Study 19183097 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric resistance exercise (ECC) program for 12 weeks, n = 10
Number of subjects: 16
Study 19183097 — intervention group
Group type: COMPARATOR
Intervention: Nonexercise control group (CON), n = 6
Number of subjects: 16
Study 16766780 — intervention group
Group type: EXPERIMENTAL
Intervention: Black tea (6 gm, caffeine 175 mg)
Number of subjects: 29
Study 16766780 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea (6 gm, caffeine 125 mg)
Number of subjects: 29
Study 16766780 — intervention group
Group type: COMPARATOR
Intervention: Caffeine (from black and green tea)
Number of subjects: 29
Study 16766780 — intervention group
Group type: COMPARATOR
Intervention: Hot water (control)
Number of subjects: 29
Study 15589006 — intervention group
Group type: EXPERIMENTAL
Intervention: BNP group (n = 93)
Number of subjects: 190
Study 11511821 — intervention group
Group type: EXPERIMENTAL
Intervention: Adefovir dipivoxil (ADV) 120 mg daily
Number of subjects: 442
Study 11511821 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 442
Study 9028689 — intervention group
Group type: COMPARATOR
Intervention: Diet intervention (n = 35)
Number of subjects: 219
Study 9028689 — intervention group
Group type: COMPARATOR
Intervention: Diet and exercise intervention (n = 67)
Number of subjects: 219
Study 9028689 — intervention group
Group type: COMPARATOR
Intervention: Exercise intervention (n = 54)
Number of subjects: 219
Study 9028689 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 43)
Number of subjects: 219
Study 8330498 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 min alcoholic disinfectant (1 min prior handwashing)
Number of subjects: 17708
Study 8330498 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 min chlorhexidine detergent (Hibiscrub), 2 min 0.5% chlorhexidine in 70% isopropanol (Hibisol)
Number of subjects: 17708
Study 8330498 — intervention group
Group type: COMPARATOR
Intervention: 5 min standard procedure
Number of subjects: 17708
Study 3088275 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 ml of 1% lidocaine
Number of subjects: 8
Study 3088275 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 ml of 1% lidocaine
Number of subjects: 8
Study 3088275 — intervention group
Group type: COMPARATOR
Intervention: 0 ml of lidocaine (control)
Number of subjects: 8
Study 29575803 — intervention group
Group type: EXPERIMENTAL
Intervention: TCZ monotherapy
Number of subjects: 296
Study 29575803 — intervention group
Group type: COMPARATOR
Intervention: TCZ plus MTX
Number of subjects: 296
Study 27634376 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial infusion of human umbilical cord-derived mesenchymal stem cells (hUC-MSCs)
Number of subjects: 9
Study 24118531 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoproterenol (ISP) and adenosine triphosphate (ATP) co-administered before and after circumferential pulmonary vein isolation (CPVI)
Number of subjects: 109
Study 24118531 — intervention group
Group type: EXPERIMENTAL
Intervention: Various pacing maneuvers with ISP+ATP
Number of subjects: 109
Study 23253702 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins (mainly Simvastatin 20 mg and Atorvastatin 10 mg)
Number of subjects: 16860
Study 23253702 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiplatelet agents
Number of subjects: 16860
Study 23253702 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 16860
Study 23253702 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitors
Number of subjects: 16860
Study 20855671 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole as single modality in patients with negative HPSA
Number of subjects: 212
Study 20855671 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole alone in patients with positive HPSA
Number of subjects: 212
Study 20855671 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy (Esomeprazole, amoxicillin sodium, and clarithromycin) in patients with positive HPSA
Number of subjects: 212
Study 19126850 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory Stroop task performance
Number of subjects: 24
Study 19126850 — intervention group
Group type: EXPERIMENTAL
Intervention: Obstacle avoidance task performance
Number of subjects: 24
Study 16884979 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane (0.5% to 1.0%)
Number of subjects: 23
Study 16884979 — intervention group
Group type: COMPARATOR
Intervention: Control (fentanyl 30 microg/kg with propofol 2-8 mg/kg/h)
Number of subjects: 23
Study 12496309 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducative group program (15 sessions, 2 hours each)
Number of subjects: 158
Study 12496309 — intervention group
Group type: COMPARATOR
Intervention: Control group (traditional support groups)
Number of subjects: 158
Study 10975425 — intervention group
Group type: EXPERIMENTAL
Intervention: Seeing-and-discriminating pretraining
Number of subjects: 0
Study 10975425 — intervention group
Group type: EXPERIMENTAL
Intervention: Seeing pretraining
Number of subjects: 0
Study 10975425 — intervention group
Group type: COMPARATOR
Intervention: Control group (no pretraining)
Number of subjects: 0
Study 9287446 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagery
Number of subjects: 47
Study 9287446 — intervention group
Group type: EXPERIMENTAL
Intervention: Support
Number of subjects: 47
Study 9287446 — intervention group
Group type: COMPARATOR
Intervention: Standard Care
Number of subjects: 47
Study 9287446 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Interventions (Imagery and Support)
Number of subjects: 47
Study 8285824 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise testing
Number of subjects: 682
Study 8285824 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory monitoring
Number of subjects: 682
Study 8285824 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment
Number of subjects: 682
Study 3320928 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefixime, 8 mg/kg daily for 10 days
Number of subjects: 120
Study 3320928 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin, 40 mg/kg/day in three divided doses for 10 days
Number of subjects: 120
Study 3320928 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefixime
Number of subjects: 120
Study 3320928 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin
Number of subjects: 120
Study 30853490 — intervention group
Group type: EXPERIMENTAL
Intervention: l-Carnitine (L-Car)
Number of subjects: 0
Study 30853490 — intervention group
Group type: COMPARATOR
Intervention: Alloisoleucine (Allo)
Number of subjects: 0
Study 30853490 — intervention group
Group type: COMPARATOR
Intervention: BCAAs and BCKAs
Number of subjects: 0
Study 30853490 — intervention group
Group type: COMPARATOR
Intervention: Restricted diet without L-Car
Number of subjects: 0
Study 30853490 — intervention group
Group type: EXPERIMENTAL
Intervention: Restricted diet with L-Car
Number of subjects: 0
Study 28127808 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist BI + EUC-B
Number of subjects: 780
Study 28127808 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer BI + EUC-B
Number of subjects: 780
Study 28127808 — intervention group
Group type: EXPERIMENTAL
Intervention: EUC-ED + EUC-B
Number of subjects: 780
Study 28127808 — intervention group
Group type: COMPARATOR
Intervention: Therapist BI
Number of subjects: 780
Study 28127808 — intervention group
Group type: COMPARATOR
Intervention: Computer BI
Number of subjects: 780
Study 25152325 — intervention group
Group type: EXPERIMENTAL
Intervention: MenACWY-TT at 12-15 months
Number of subjects: 100
Study 25152325 — intervention group
Group type: EXPERIMENTAL
Intervention: MenACWY-TT + DTaP at 15-18 months
Number of subjects: 100
Study 25152325 — intervention group
Group type: EXPERIMENTAL
Intervention: HibMenCY-TT at 12-15 months
Number of subjects: 100
Study 25152325 — intervention group
Group type: COMPARATOR
Intervention: DTaP only at 15-18 months (Control)
Number of subjects: 100
Study 22589422 — intervention group
Group type: EXPERIMENTAL
Intervention: NRT + MI
Number of subjects: 430
Study 22589422 — intervention group
Group type: COMPARATOR
Intervention: NRT + Brief Advice
Number of subjects: 430
Study 20888580 — intervention group
Group type: EXPERIMENTAL
Intervention: Ghrelin (50 μg)
Number of subjects: 14
Study 18222449 — intervention group
Group type: EXPERIMENTAL
Intervention: Midcycle pericoital vaginal applications of a mixture of Egyptian bee honey and royal jelly (H/RJ)
Number of subjects: 99
Study 18222449 — intervention group
Group type: COMPARATOR
Intervention: Standard intrauterine insemination (IUI) procedure
Number of subjects: 99
Study 16936417 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF) - 2-5 microg/kg subcutaneous injection once daily for 10 days
Number of subjects: 39
Study 16936417 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone marrow transplantation (BMT) - conventional drug therapy plus BMT
Number of subjects: 39
Study 16936417 — intervention group
Group type: COMPARATOR
Intervention: Conventional drug therapy
Number of subjects: 39
Study 12968843 — intervention group
Group type: EXPERIMENTAL
Intervention: Icodextrin during the 12-hour long dwell for 6 weeks
Number of subjects: 18
Study 10720011 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretic administration
Number of subjects: 9
Study 10720011 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 8707483 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily massages for one month
Number of subjects: 29
Study 1514711 — intervention group
Group type: EXPERIMENTAL
Intervention: captopril 25-50 mg twice daily
Number of subjects: 12
Study 1514711 — intervention group
Group type: COMPARATOR
Intervention: nifedipine SR 20-40 mg twice daily
Number of subjects: 12
Study 6096193 — intervention group
Group type: EXPERIMENTAL
Intervention: High fibre, low fat and low sodium diet
Number of subjects: 50
Study 6096193 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 50
Study 31517848 — intervention group
Group type: EXPERIMENTAL
Intervention: Buyang Huanwu Tang (BHT)
Number of subjects: 0
Study 31517848 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 30200162 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunct intermittent pneumatic compression with pharmacologic thromboprophylaxis
Number of subjects: 0
Study 30200162 — intervention group
Group type: COMPARATOR
Intervention: Pharmacologic thromboprophylaxis alone
Number of subjects: 0
Study 27290978 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex
Number of subjects: 72
Study 27290978 — intervention group
Group type: COMPARATOR
Intervention: Neostigmine
Number of subjects: 72
Study 27290978 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 72
Study 24383508 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate ingestion throughout (CC)
Number of subjects: 8
Study 24383508 — intervention group
Group type: EXPERIMENTAL
Intervention: Late carbohydrate ingestion (PC)
Number of subjects: 8
Study 24383508 — intervention group
Group type: COMPARATOR
Intervention: No carbohydrate ingestion (PP)
Number of subjects: 8
Study 24383508 — intervention group
Group type: EXPERIMENTAL
Intervention: Early carbohydrate ingestion (CP)
Number of subjects: 8
Study 22401984 — intervention group
Group type: EXPERIMENTAL
Intervention: Hard insole
Number of subjects: 0
Study 22401984 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft insole
Number of subjects: 0
Study 22401984 — intervention group
Group type: COMPARATOR
Intervention: Barefoot condition (Control)
Number of subjects: 0
Study 20851295 — intervention group
Group type: EXPERIMENTAL
Intervention: Folate (5 mg) plus vitamin B12 (500 μg) supplementation
Number of subjects: 44
Study 20851295 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 17545906 — intervention group
Group type: EXPERIMENTAL
Intervention: CT scanning and passive rotation
Number of subjects: 20
Study 15008770 — intervention group
Group type: EXPERIMENTAL
Intervention: Preclosure analgesia (saline before incision and lignocaine before closure)
Number of subjects: 144
Study 15008770 — intervention group
Group type: EXPERIMENTAL
Intervention: Preemptive analgesia (lignocaine before incision and saline before closure)
Number of subjects: 144
Study 15008770 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline before incision and closure)
Number of subjects: 144